Does the media prefer CDXS or HBIO?

In the previous week, Harvard Bioscience had 11 more articles in the media than Codexis. MarketBeat recorded 13 mentions for Harvard Bioscience and 2 mentions for Codexis. Harvard Bioscience's average media sentiment score of 0.87 beat Codexis' score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer QTRX or HBIO?

In the previous week, Harvard Bioscience had 11 more articles in the media than Quanterix. MarketBeat recorded 13 mentions for Harvard Bioscience and 2 mentions for Quanterix. Harvard Bioscience's average media sentiment score of 0.87 beat Quanterix's score of 0.17 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quanterix 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SEER or HBIO?

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Seer $16.58M 5.68 -$73.60M -$1.22 N/A Harvard Bioscience $86.55M 0.45 -$56.70M -$2.31 N/A

Is SEER or HBIO more profitable?

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% Harvard Bioscience -11.86% -33.13% -4.80%

Does the media prefer SEER or HBIO?

In the previous week, Harvard Bioscience had 7 more articles in the media than Seer. MarketBeat recorded 13 mentions for Harvard Bioscience and 6 mentions for Seer. Harvard Bioscience's average media sentiment score of 0.87 beat Seer's score of 0.01 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seer 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CSBR or HBIO?

Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 21.60%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate IBAC or HBIO?

Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 21.60%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, IBAC or HBIO?

IB Acquisition has higher earnings, but lower revenue than Harvard Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Harvard Bioscience $86.55M 0.45 -$56.70M -$2.31 N/A

Does the media prefer IBAC or HBIO?

In the previous week, Harvard Bioscience had 12 more articles in the media than IB Acquisition. MarketBeat recorded 13 mentions for Harvard Bioscience and 1 mentions for IB Acquisition. Harvard Bioscience's average media sentiment score of 0.87 beat IB Acquisition's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IB Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Harvard Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Harvard Bioscience (HBIO) Competitors

$8.43 -0.19 (-2.15%)

As of 01:12 PM Eastern

Compare

HBIO vs. CDXS, QTRX, SEER, CSBR, and IBAC

Should you buy Harvard Bioscience stock or one of its competitors? Harvard Bioscience's main competitors and comparable companies include Codexis (CDXS), Quanterix (QTRX), Seer (SEER), Champions Oncology (CSBR), and IB Acquisition (IBAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to Codexis?

Codexis (NASDAQ:CDXS) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

78.5% of Codexis shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Codexis currently has a consensus target price of $6.50, indicating a potential upside of 501.85%. Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 21.60%. Given Codexis' stronger consensus rating and higher possible upside, analysts clearly believe Codexis is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Codexis has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

In the previous week, Harvard Bioscience had 11 more articles in the media than Codexis. MarketBeat recorded 13 mentions for Harvard Bioscience and 2 mentions for Codexis. Harvard Bioscience's average media sentiment score of 0.87 beat Codexis' score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	1.68	-$43.97M	-$0.34	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

Harvard Bioscience has a net margin of -11.86% compared to Codexis' net margin of -39.55%. Harvard Bioscience's return on equity of -33.13% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Summary

Harvard Bioscience beats Codexis on 8 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Quanterix currently has a consensus target price of $3.25, suggesting a potential upside of 6.91%. Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 21.60%. Given Quanterix's higher probable upside, equities research analysts plainly believe Quanterix is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Harvard Bioscience had 11 more articles in the media than Quanterix. MarketBeat recorded 13 mentions for Harvard Bioscience and 2 mentions for Quanterix. Harvard Bioscience's average media sentiment score of 0.87 beat Quanterix's score of 0.17 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quanterix	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harvard Bioscience has a net margin of -11.86% compared to Quanterix's net margin of -80.25%. Quanterix's return on equity of -26.09% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

86.5% of Quanterix shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 1.5% of Quanterix shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harvard Bioscience has lower revenue, but higher earnings than Quanterix. Harvard Bioscience is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.04	-$107.15M	-$2.63	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

Quanterix has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Summary

Harvard Bioscience beats Quanterix on 10 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to Seer?

Seer (NASDAQ:SEER) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Seer currently has a consensus target price of $4.00, suggesting a potential upside of 135.29%. Harvard Bioscience has a consensus target price of $6.75, suggesting a potential downside of 21.60%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Harvard Bioscience had 7 more articles in the media than Seer. MarketBeat recorded 13 mentions for Harvard Bioscience and 6 mentions for Seer. Harvard Bioscience's average media sentiment score of 0.87 beat Seer's score of 0.01 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seer	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

75.2% of Seer shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 11.3% of Seer shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Seer has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	5.68	-$73.60M	-$1.22	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

Summary

Harvard Bioscience beats Seer on 9 of the 16 factors compared between the two stocks.

How does Harvard Bioscience compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Champions Oncology has higher earnings, but lower revenue than Harvard Bioscience. Champions Oncology is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.13	-$1.17M	-$0.08	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

In the previous week, Harvard Bioscience had 13 more articles in the media than Champions Oncology. MarketBeat recorded 13 mentions for Harvard Bioscience and 0 mentions for Champions Oncology. Harvard Bioscience's average media sentiment score of 0.87 beat Champions Oncology's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Champions Oncology	Neutral
Harvard Bioscience	Positive

41.3% of Champions Oncology shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 46.3% of Champions Oncology shares are owned by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Champions Oncology has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Champions Oncology has a net margin of -1.82% compared to Harvard Bioscience's net margin of -11.86%. Champions Oncology's return on equity of -25.77% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 21.60%. Given Harvard Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Harvard Bioscience is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Harvard Bioscience beats Champions Oncology on 8 of the 15 factors compared between the two stocks.

How does Harvard Bioscience compare to IB Acquisition?

IB Acquisition (NASDAQ:IBAC) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

In the previous week, Harvard Bioscience had 12 more articles in the media than IB Acquisition. MarketBeat recorded 13 mentions for Harvard Bioscience and 1 mentions for IB Acquisition. Harvard Bioscience's average media sentiment score of 0.87 beat IB Acquisition's score of 0.00 indicating that Harvard Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IB Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IB Acquisition has a net margin of 0.00% compared to Harvard Bioscience's net margin of -11.86%. IB Acquisition's return on equity of 0.00% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Harvard Bioscience	-11.86%	-33.13%	-4.80%

IB Acquisition has higher earnings, but lower revenue than Harvard Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

80.9% of Harvard Bioscience shares are held by institutional investors. 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Harvard Bioscience has a consensus price target of $6.75, suggesting a potential downside of 21.60%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Harvard Bioscience beats IB Acquisition on 8 of the 11 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.33M	$10.70B	$7.85B	$11.72B
Dividend Yield	N/A	1.47%	2.48%	4.43%
P/E Ratio	-3.65	43.30	35.36	31.48
Price / Sales	0.44	6.96	8.34	5.61
Price / Cash	0.74	27.46	21.67	22.93
Price / Book	2.74	4.22	4.64	3.85
Net Income	-$56.70M	$56.67B	$3.50B	$381.65M
7 Day Performance	-4.26%	-6.76%	-3.87%	-5.34%
1 Month Performance	-0.88%	-6.40%	-7.06%	-9.42%
1 Year Performance	43.11%	18.81%	0.75%	-9.13%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	1.4573 of 5 stars	$8.43 -2.1%	$6.75 -19.9%	+39.7%	$38.33M	$86.55M	N/A	339	Trending News Upcoming Earnings Analyst Forecast Analyst Revision
CDXS Codexis	2.5748 of 5 stars	$1.28 -1.5%	$6.50 +407.8%	-50.2%	$140.17M	$70.39M	N/A	146
QTRX Quanterix	1.7248 of 5 stars	$2.89 +2.1%	$3.25 +12.5%	-41.7%	$136.68M	$153.17M	N/A	450	Positive News Upcoming Earnings
SEER Seer	3.9369 of 5 stars	$1.96 +1.6%	$4.00 +104.1%	-22.4%	$108.53M	$16.58M	N/A	124	Upcoming Earnings
CSBR Champions Oncology	0.145 of 5 stars	$4.83 -0.6%	N/A	-29.1%	$67.23M	$59.42M	N/A	214	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 11/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. CDXS, QTRX, SEER, CSBR, and IBAC

How does Harvard Bioscience compare to Codexis?

Summary

How does Harvard Bioscience compare to Quanterix?

Summary

How does Harvard Bioscience compare to Seer?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Summary

How does Harvard Bioscience compare to IB Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. CDXS, QTRX, SEER, CSBR, and IBAC

How does Harvard Bioscience compare to Codexis?

Do insiders & institutionals have more ownership in CDXS or HBIO?

Do analysts rate CDXS or HBIO?

Which has more volatility and risk, CDXS or HBIO?

Does the media prefer CDXS or HBIO?

Which has higher valuation & earnings, CDXS or HBIO?

Is CDXS or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Quanterix?

Do analysts prefer QTRX or HBIO?

Does the media prefer QTRX or HBIO?

Is QTRX or HBIO more profitable?

Do institutionals and insiders hold more shares of QTRX or HBIO?

Which has better valuation & earnings, QTRX or HBIO?

Which has more risk and volatility, QTRX or HBIO?

Summary

How does Harvard Bioscience compare to Seer?

Do analysts rate SEER or HBIO?

Does the media prefer SEER or HBIO?

Do institutionals and insiders have more ownership in SEER or HBIO?

Which has more volatility & risk, SEER or HBIO?

Is SEER or HBIO more profitable?

Which has better earnings and valuation, SEER or HBIO?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Which has preferable earnings and valuation, CSBR or HBIO?

Does the media prefer CSBR or HBIO?

Do institutionals and insiders have more ownership in CSBR or HBIO?

Which has more risk and volatility, CSBR or HBIO?

Is CSBR or HBIO more profitable?

Do analysts prefer CSBR or HBIO?

Summary

How does Harvard Bioscience compare to IB Acquisition?

Does the media prefer IBAC or HBIO?

Is IBAC or HBIO more profitable?

Which has better valuation & earnings, IBAC or HBIO?

Do insiders and institutionals have more ownership in IBAC or HBIO?

Do analysts rate IBAC or HBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools